FDA Clears Dose Control System
Radiation oncology solutions provider Accuray Inc., Sunnyvale, Calif., today announced that it has obtained 510(k) clearance from the Food and Drug Administration (FDA) to market its Dose Control System (DCS). DCS is a new feature for Accuray’s TomoTherapy® System. It automatically adjusts controls that were previously handled through a manual process, thereby correcting small variations in dose rate and minimizing interruptions. The DCS application is also said to ensure a more stable output over longer duration treatments, such as total marrow and total body Irradiation. Read the press release.